Advent Bioservices vs Emergent BioSolutions (CGT): CDMO Comparison
Side-by-side comparison of Advent Bioservices and Emergent BioSolutions (CGT) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Advent Bioservices maintains 2 MHRA / UK GMP certificates; Emergent BioSolutions (CGT) does not.
On a 13-modality CDMO landscape, both Advent Bioservices and Emergent BioSolutions (CGT) qualify as AAV manufacturers; Advent Bioservices carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Advent Bioservices and Emergent BioSolutions (CGT) qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Advent Bioservices vs Emergent BioSolutions (CGT)
How do Advent Bioservices and Emergent BioSolutions (CGT) compare on European GMP coverage?
Advent Bioservices holds 0 active EMA GMP certificates and 2 MHRA / UK certificates. Emergent BioSolutions (CGT) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Advent Bioservices or Emergent BioSolutions (CGT)?
Advent Bioservices is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Emergent BioSolutions (CGT) is matched to 4. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — Advent Bioservices or Emergent BioSolutions (CGT)?
Both Advent Bioservices and Emergent BioSolutions (CGT) are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Advent Bioservices carries a Signal Score of 78/100 and Emergent BioSolutions (CGT) carries 71/100 — a small lead for Advent Bioservices. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →